HER2 dual anti-KN026 combined with chemotherapy for the treatment of gastric cancer is clinically approved

On January 4, Corning Jereh and CSPC jointly announced that a registered clinical trial (KN026-CSP-001) of the HER2 bispecific antibody KN026 combined with chemotherapy has been applied for by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.

KN026-CSP-001 is a randomized, multicenter, phase II/III clinical study to evaluate the effectiveness and safety of KN026 combined with chemotherapy in patients with HER2-positive gastric cancer (including gastric-esophageal junction adenocarcinoma) who have failed first-line treatment , Professor Xu Jianming from the General Hospital of the Chinese People’s Liberation Army served as the principal investigator

Gastric cancer and adenocarcinoma of the gastroesophageal junction are one of the common malignant tumors.

KN026's Phase II study data released at the ASCO annual meeting in 2021 shows that KN026 is effective in treating patients with advanced HER2-positive gastric and gastroesophageal junction adenocarcinoma, regardless of whether the patient has previously received trastuzumab therapy: in patients with high HER2 expression , The objective response rate (ORR) was 55.

Note: The original text has been deleted